KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Change in Accured Expenses (2016 - 2025)

LifeMD (LFMD) has disclosed Change in Accured Expenses for 14 consecutive years, with -$5.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 260.43% year-over-year to -$5.1 million, compared with a TTM value of -$5.8 million through Dec 2025, down 153.77%, and an annual FY2025 reading of -$5.8 million, down 153.77% over the prior year.
  • Change in Accured Expenses was -$5.1 million for Q4 2025 at LifeMD, down from -$1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.2 million in Q3 2024 and bottomed at -$6.2 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $602488.6, with a median of $882322.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 1340.26% in 2023, while the deepest fall reached 723.1% in 2023.
  • Year by year, Change in Accured Expenses stood at $771146.0 in 2021, then grew by 28.83% to $993498.0 in 2022, then plummeted by 723.1% to -$6.2 million in 2023, then skyrocketed by 150.86% to $3.1 million in 2024, then crashed by 260.43% to -$5.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for LFMD at -$5.1 million in Q4 2025, -$1.2 million in Q3 2025, and $2.8 million in Q2 2025.